These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 22924734)

  • 1. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
    Cui JJ; McTigue M; Nambu M; Tran-Dubé M; Pairish M; Shen H; Jia L; Cheng H; Hoffman J; Le P; Jalaie M; Goetz GH; Ryan K; Grodsky N; Deng YL; Parker M; Timofeevski S; Murray BW; Yamazaki S; Aguirre S; Li Q; Zou H; Christensen J
    J Med Chem; 2012 Sep; 55(18):8091-109. PubMed ID: 22924734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.
    Zhao F; Zhang LD; Hao Y; Chen N; Bai R; Wang YJ; Zhang CC; Li GS; Hao LJ; Shi C; Zhang J; Mao Y; Fan Y; Xia GX; Yu JX; Liu YJ
    Eur J Med Chem; 2017 Jul; 134():147-158. PubMed ID: 28411455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer.
    Jia H; Dai G; Weng J; Zhang Z; Wang Q; Zhou F; Jiao L; Cui Y; Ren Y; Fan S; Zhou J; Qing W; Gu Y; Wang J; Sai Y; Su W
    J Med Chem; 2014 Sep; 57(18):7577-89. PubMed ID: 25148209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met.
    Northrup AB; Katcher MH; Altman MD; Chenard M; Daniels MH; Deshmukh SV; Falcone D; Guerin DJ; Hatch H; Li C; Lu W; Lutterbach B; Allison TJ; Patel SB; Reilly JF; Reutershan M; Rickert KW; Rosenstein C; Soisson SM; Szewczak AA; Walker D; Wilson K; Young JR; Pan BS; Dinsmore CJ
    J Med Chem; 2013 Mar; 56(6):2294-310. PubMed ID: 23379595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.
    Boezio AA; Copeland KW; Rex K; K Albrecht B; Bauer D; Bellon SF; Boezio C; Broome MA; Choquette D; Coxon A; Dussault I; Hirai S; Lewis R; Lin MH; Lohman J; Liu J; Peterson EA; Potashman M; Shimanovich R; Teffera Y; Whittington DA; Vaida KR; Harmange JC
    J Med Chem; 2016 Mar; 59(6):2328-42. PubMed ID: 26812066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
    Zhang L; Zhao J; Zhang B; Lu T; Chen Y
    Eur J Med Chem; 2018 Apr; 150():809-816. PubMed ID: 29602036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.
    Cui JJ; Shen H; Tran-Dubé M; Nambu M; McTigue M; Grodsky N; Ryan K; Yamazaki S; Aguirre S; Parker M; Li Q; Zou H; Christensen J
    J Med Chem; 2013 Sep; 56(17):6651-65. PubMed ID: 23944843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
    Timofeevski SL; McTigue MA; Ryan K; Cui J; Zou HY; Zhu JX; Chau F; Alton G; Karlicek S; Christensen JG; Murray BW
    Biochemistry; 2009 Jun; 48(23):5339-49. PubMed ID: 19459657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
    Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.
    Buchanan SG; Hendle J; Lee PS; Smith CR; Bounaud PY; Jessen KA; Tang CM; Huser NH; Felce JD; Froning KJ; Peterman MC; Aubol BE; Gessert SF; Sauder JM; Schwinn KD; Russell M; Rooney IA; Adams J; Leon BC; Do TH; Blaney JM; Sprengeler PA; Thompson DA; Smyth L; Pelletier LA; Atwell S; Holme K; Wasserman SR; Emtage S; Burley SK; Reich SH
    Mol Cancer Ther; 2009 Dec; 8(12):3181-90. PubMed ID: 19934279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors.
    Liu J; Nie M; Wang Y; Hu J; Zhang F; Gao Y; Liu Y; Gong P
    Eur J Med Chem; 2016 Nov; 123():431-446. PubMed ID: 27490023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
    Zhao F; Zhang J; Zhang L; Hao Y; Shi C; Xia G; Yu J; Liu Y
    Bioorg Med Chem; 2016 Sep; 24(18):4281-4290. PubMed ID: 27448775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
    Cui JJ; Tran-Dubé M; Shen H; Nambu M; Kung PP; Pairish M; Jia L; Meng J; Funk L; Botrous I; McTigue M; Grodsky N; Ryan K; Padrique E; Alton G; Timofeevski S; Yamazaki S; Li Q; Zou H; Christensen J; Mroczkowski B; Bender S; Kania RS; Edwards MP
    J Med Chem; 2011 Sep; 54(18):6342-63. PubMed ID: 21812414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insight into the key features for ligand binding in Y1230 mutated c-Met kinase domain by molecular dynamics simulations.
    Yan L; Zhang L; Zhang Y; Qiao X; Pan J; Liu H; Lu S; Xiang B; Lu T; Yuan H
    J Biomol Struct Dyn; 2018 Jun; 36(8):2015-2031. PubMed ID: 28599617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
    Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
    Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
    Yamazaki S; Skaptason J; Romero D; Vekich S; Jones HM; Tan W; Wilner KD; Koudriakova T
    Drug Metab Dispos; 2011 Mar; 39(3):383-93. PubMed ID: 21098644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. O-linked triazolotriazines: potent and selective c-Met inhibitors.
    Chen F; Wang Y; Ai J; Zhan Z; Lv Y; Liang Z; Luo C; Mei D; Geng M; Duan W
    ChemMedChem; 2012 Jul; 7(7):1276-85. PubMed ID: 22539497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.
    Bode CM; Boezio AA; Albrecht BK; Bellon SF; Berry L; Broome MA; Choquette D; Dussault I; Lewis RT; Lin MH; Rex K; Whittington DA; Yang Y; Harmange JC
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4089-93. PubMed ID: 22595176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors.
    Peterson EA; Teffera Y; Albrecht BK; Bauer D; Bellon SF; Boezio A; Boezio C; Broome MA; Choquette D; Copeland KW; Dussault I; Lewis R; Lin MH; Lohman J; Liu J; Potashman M; Rex K; Shimanovich R; Whittington DA; Vaida KR; Harmange JC
    J Med Chem; 2015 Mar; 58(5):2417-30. PubMed ID: 25699405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115.
    Mortensen DS; Perrin-Ninkovic SM; Shevlin G; Elsner J; Zhao J; Whitefield B; Tehrani L; Sapienza J; Riggs JR; Parnes JS; Papa P; Packard G; Lee BG; Harris R; Correa M; Bahmanyar S; Richardson SJ; Peng SX; Leisten J; Khambatta G; Hickman M; Gamez JC; Bisonette RR; Apuy J; Cathers BE; Canan SS; Moghaddam MF; Raymon HK; Worland P; Narla RK; Fultz KE; Sankar S
    J Med Chem; 2015 Jul; 58(14):5599-608. PubMed ID: 26102506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.